TMA-2
2,4,5-trimethoxyamphetamine
Lethal interactions
| Combination | Type | Severity | Mechanisms | Confidence |
|---|---|---|---|---|
| MAOIs | Drug class | lethal | 2 | high |
Dangerous interactions
26 dangerous interactions recorded for this substance.
See the full interactions tableContraindications
| Condition | Severity | Note |
|---|---|---|
| Cardiovascular | ||
| uncontrolled hypertension | relative | Hypertension, arrhythmias, coronary artery disease, or structural heart disease. Vasoconstriction and tachycardia are reported effects. No controlled cardiovascular data exist. |
| cardiac arrhythmias | relative | Pre-existing arrhythmias may be worsened by TMA-2's reported cardiac effects and prolonged stimulant activity. |
| Neurological | ||
| epilepsy | relative | Seizure disorders or history of seizures. Phenethylamine psychedelics increase cortical excitability. No TMA-2-specific seizure data. |
| Psychiatric | ||
| psychotic disorders | absolute | Personal or family history of schizophrenia, schizoaffective disorder, or other psychotic disorders. Class-level contraindication for all serotonergic psychedelics. |
| bipolar disorder | absolute | Bipolar I and II disorder. Risk of precipitating manic episodes. Class-level contraindication for serotonergic psychedelics. |
| Pregnancy & Breastfeeding | ||
| pregnancy | absolute | Pregnancy and breastfeeding. No safety data available. 5-HT2A agonists may disrupt fetal serotonergic neurodevelopment. |
| Other | ||
| concurrent MAOI use | absolute | Concurrent use of MAO inhibitors (pharmaceutical or traditional) is contraindicated due to serotonin syndrome risk. Class-level contraindication for serotonergic psychedelics. |
| concurrent lithium use | absolute | Concurrent lithium therapy. Class-level interaction flagged across serotonergic psychedelics for seizure risk and unpredictable potentiation. |